Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required

Bone Marrow Transplant. 2019 Aug;54(8):1372-1373. doi: 10.1038/s41409-019-0488-2. Epub 2019 Feb 25.

Authors

Tiene Bauters¹, Victoria Bordon², Geneviève Laureys², Catharina Dhooge²

Affiliations

¹ Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium. [email protected].
² Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium.

PMID: 30804487
DOI: 10.1038/s41409-019-0488-2

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Humans
Hypertriglyceridemia / chemically induced*
Janus Kinases / adverse effects*
Nitriles
Pyrazoles / adverse effects*
Pyrimidines
Sirolimus / adverse effects*
Triglycerides / blood*

Substances

Nitriles
Pyrazoles
Pyrimidines
Triglycerides
ruxolitinib
Janus Kinases
Sirolimus